Skip to main content
Full access
Clinical and Research News
Published Online: 12 June 2013

Brain Imaging, Other Advances Reveal Drugs’ Effects on Brain

New understanding of how drugs of abuse affect dopamine reward circuitry is providing insights into potential new therapies.
Nora Volkow, M.D.: Increasing—and sometimes surprising—advances in research are fueling a better understanding of the mechanisms of drug addiction and potential treatments.
David Hathcox
“The universe of a person who is addicted is narrowed to the drug, and that is the challenge and the incredible opportunity we have as psychiatrists to help these individuals,” said Nora Volkow, M.D., director of the National Institute on Drug Abuse, at APA’s 2013 annual meeting in San Francisco last month.
Research in recent years using brain imaging techniques has provided new insights into the mechanism of addiction while simultaneously unsettling elements of what once was the common wisdom, she said.
All drugs of abuse increase dopamine, which is crucial for their effect, she said. They also trigger neuroplasticity changes that result in addiction, but more dopamine does not explain addiction.
Among both lab animals and humans, voluntary initiation of drug use leads to a subsequent loss of control and development of addiction among about 10 percent of subjects. The lab rats and mice are useful for refuting old stereotypes.
Some people still consider addiction moral turpitude, she said. “But how can you develop the same phenotype in a rat, which has no moral precepts?”
Other ideas about addiction have also changed in recent years, she said. Once it was thought that addicts were overly sensitive to dopaminergic effects, but now it appears that they have an attenuated response in the dopamine system to drug consumption.
Repeated drug use leads to less D2 receptor pathway signaling, inhibiting sensitivity to reward, she said.
This makes evolutionary sense as the reward value of dopamine signaling shifts from consumption of drugs or food to expectation and stimulus.
“As in addiction, it motivates your behavior to get that reward,” she said. “Once consumed, it doesn’t matter. You don’t need to motivate behavior then.”
For example, simply showing videos to addicts of people using cocaine releases dopamine in the striatum and provokes a desire for the drug. This may also explain why it is better for psychiatrists to help patients avoid settings where they risk taking drugs, rather than having to intervene once they have started using again.
Yet another discovery is that addiction is not solely a property of the limbic system but also involves the prefrontal cortex, said Volkow. D1 and D2 receptors there are important for normal executive function. However, D2 expression is lower during addiction to cocaine, methamphetamine, alcohol, heroin, and nicotine (but not marijuana). Reduced D2 receptor signaling in addiction decreases inhibitory control in the prefrontal area, letting up on the neural “brakes” on compulsive drug use.
“That’s why the process of addiction becomes so ingrained and why patients go to tremendous effort to get drugs at such a horrific price,” she said. Awareness of deficits in the prefrontal cortex can help psychiatrists treat addicted individuals using approaches that allow them to assert better self-control, extinguish conditioned responses to drugs, and enhance the value of alternative rewards.
A third insight has come from genetic studies of smoking. Three alleles for nicotine receptors—α5, α3, and β4—are heavily concentrated in the habenula, a region that has been targeted by deep brain stimulation for treatment of depression.
“That may be related to the antidepressant properties of smoking,” she speculated.
Nevertheless, no single area of the brain is implicated in addiction, she said. “Multiple circuits are disrupted as they are in other mental illnesses, like schizophrenia, ADHD, and mood disorders.”
Perhaps as a consequence, the treatment of addiction requires a multipronged approach to strengthen brain circuits that have been impaired by the use of drugs, she said. Thus, in addition to research into behavioral and medical treatments, NIDA also is funding a search for vaccines to produce antibodies that would bind to cocaine, heroin, methamphetamine, and other addictive substances in the bloodstream and prevent their entry into the brain.
“These are some of the most exciting areas of science in the field of drug addiction,” said Volkow. ■
An extended discussion of addiction and reward circuitry by Nora Volkow and colleagues is posted at http://www.pnas.org/content/108/37/15037.full. To watch a video interview with Volkow, go to http://www.youtube.com/watch?v=zXzU9uFF5G0.

Information & Authors

Information

Published In

History

Published online: 12 June 2013
Published in print: June 8, 2013 – June 21, 2013

Keywords

  1. Nora Volkow
  2. Drug addiction
  3. NIDA
  4. National Institute on Drug Abuse
  5. psychiatry
  6. APA
  7. dopamine

Authors

Affiliations

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share